Serial myocardial perfusion imaging (MPI) is valuable for assessing coronary disease progression and treatment efficacy. Previous serial MPI studies emphasized severe perfusion defects, with no attention given to milder perfusion defects. Thus, this study sought to compare and identify predictors of change in severe versus mild perfusion defect size in patients who underwent serial positron emission tomography (PET) MPI. Serial PET MPI was performed in 551 patients with an average of 1.9 years between scans. Severe and mild perfusion defect size at both PETs were derived from automated software as percentage of left ventricular mass with relative tracer activity <60% (severe) and between 61% and 80% of maximum tracer activity (mild), respectively. Predictors of change in severe and mild perfusion defect size between PETs were determined. Overall, severe perfusion defect sizes improved (p <0.001) and mild perfusion defect sizes worsened (p <0.001) between PETs with individual changes being highly variable. In individuals with negligible changes in severe defect size (±2%), changes in mild defect size ranged from a worsening of 47% to an improvement of 48% of left ventricular mass. The strongest predictors of change in severe defect size were indicators of obstructive coronary disease including interval myocardial infarction, interval revascularization, history of myocardial infarction, and history of bypass surgery. Strong predictors of change in mild defect size were cardiac risk factors including male gender, body mass index, diabetes, and smoking. In conclusion, changes in mild perfusion defects may provide valuable secondary information for evaluating treatment efficacy in patients who underwent serial MPI.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Tracking a therapeutic response: how reliable are serial measurements of LV perfusion and function?.J Nucl Cardiol. 2012; 19: 360-363
- Clinical Guidelines Committee of the American College of Physicians. Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons.Ann Intern Med. 2012; 157: 729-734
- Physiological assessment of myocardial perfusion using nuclear cardiology would enhance coronary artery disease patient care: which imaging modality is best for evaluation of myocardial ischemia? (SPECT-Side).Circ J. 2011; 75: 713-723
- Patient management after noninvasive cardiac imaging: results from SPARC (Study of Myocardial Perfusion and Coronary Anatomy Imaging Roles in Coronary Artery Disease).J Am Coll Cardiol. 2012; 59: 462-474
- Evaluating the prognostic value of positron emission tomography myocardial perfusion imaging using automated software to calculate perfusion defect size.Clin Cardiol. 2012; 35: E14-E21
- Impact of myocardial perfusion imaging with PET and 82Rb on downstream invasive procedure utilization, costs, and outcomes in coronary disease management.J Nucl Med. 2007; 48: 1069-1076
- Mechanisms of progression and regression of coronary artery disease by PET related to treatment intensity and clinical events at long-term follow-up.J Nucl Med. 2006; 47: 59-67
- Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease.J Am Coll Cardiol. 2003; 41: 263-272
- Assessing progression and regression of CAD: the role of perfusion imaging.J Nucl Cardiol. 2005; 12: 625-638
- Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.Circulation. 2008; 117: 1283-1291
- Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification.JAMA. 1995; 274: 894-901
- The clinical value of myocardial blood flow measurement.J Nucl Med. 2009; 50: 1076-1087
- Detecting the impact of emerging cardiovascular disease risk factors: the role of positron emission tomography.J Nucl Cardiol. 2008; 15: 485-490
- Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease.Eur J Nucl Med Mol Imaging. 2006; 33: 1150-1156
- The prognostic value of mild perfusion defects as identified by rubidium-82 positron emission tomography myocardial perfusion imaging.Circulation. 2010; 122 (A21400)
- Cardiac positron emission tomography.J Am Coll Cardiol. 2009; 54: 1-15
- Quantitative analysis of perfusion studies: strengths and pitfalls.J Nucl Cardiol. 2012; 19: 338-346
- Integrating noninvasive absolute flow, coronary flow reserve, and ischemic thresholds into a comprehensive map of physiological severity.J Am Coll Cardiol Img. 2012; 5: 430-440
- PET perfusion imaging and nuclear cardiology.J Nucl Med. 1991; 32: 579-606
Published online: August 26, 2014
Accepted: August 5, 2014
Received in revised form: August 5, 2014
Received: May 7, 2014
This work was funded by the American Heart Association, University at Buffalo, and Niagara Falls Memorial Medical Center.
See page 1517 for disclosure information.
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.